| |
- Partnership will evaluate advanced ultrasound technologies to improve early detection and monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease
- Advancing ultrasound technologies that are safer, more accessible alternatives to invasive diagnostic procedures
- Research led by globally respected hepatologist Associate Professor Dan Yock Young
SINGAPORE, Oct. 8, 2025 /PRNewswire/ -- Siemens Healthineers and the National University Hospital (NUH) Singapore have announced a strategic research collaboration to advance diagnostic solutions for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects nearly 40% of adults in Singapore — a prevalence that is higher than the global average of 30.05%.
MASLD, formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), is now the most common cause of chronic liver disease worldwide. The elevated burden in Singapore reflects rising levels of obesity, sedentary lifestyles, and associated metabolic conditions – a serious trend that demands a more efficient, patient-friendly approach to liver care.
The research initiative will be led by Associate Professor Dan Yock Young, Senior Consultant, Division of Gastroenterology and Hepatology, Department of Medicine at NUH, and Associate Professor, Department of Medicine at the Yong Loo Lin School of Medicine, National University of Singapore. A globally respected hepatologist, his pioneering contributions to liver disease research have set international benchmarks. His leadership lends both clinical excellence and a global perspective to the project.
The collaborative study will evaluate Siemens Healthineers' cutting-edge ultrasound technologies: Ultrasound-Derived Fat Fraction (UDFF) and Auto Point Shear Wave Elastography (Auto pSWE). These tools enable physicians to non-invasively measure both liver fat and stiffness in a single, streamlined session, offering safer and more cost-effective alternatives to MRI scans and invasive biopsies. Early detection, more precise monitoring, and timely intervention could redefine the liver care pathway across the region.
"Together with NUH, led by Associate Professor Dan Yock Young, we will study how advanced ultrasound technologies can transform liver care by offering a cost-effective alternative to invasive biopsy or high-cost imaging," said Vy Tran, President Asia-Pacific Japan, Siemens Healthineers. "Our aim is to make ultrasound technologies accessible not only in tertiary hospitals but also at the polyclinic level. If we can embed these solutions into the liver care pathway, we can bring earlier detection, better monitoring and timely interventions to the people who need it. With this research collaboration, we hope to create new opportunities to scale the adoption of ultrasound technologies and improve clinical outcomes for liver patients across the Asia Pacific region."
"This collaboration represents an important step forward in addressing MASLD, which is fast emerging as a major health burden in Singapore," said Associate Professor Dan Yock Young. "At NUH, we combine deep clinical expertise in liver and metabolic health, backed by strong translational research. By working with partners such as Siemens Healthineers, we are well positioned to pioneer new approaches to detect, treat and prevent the disease, thereby helping more patients live healthier lives."
The initiative is part of the upcoming National University Centre for Digestive Health, set to open in January 2026, which aims to enhance patient access to cutting-edge diagnostic innovations.
"With nearly 40% of adults in Singapore affected, fatty liver disease is a silent epidemic we can no longer ignore. This collaboration reflects our shared responsibility to change that story. By bringing ultrasound innovation to the frontlines of care, we can empower physicians with better tools and offer patients not just accurate diagnostics, but hope for a healthier future," said Chaitanya Mehrotra, Head of Ultrasound, Asia Pacific, Siemens Healthineers.
This partnership leverages NUH's clinical expertise alongside Siemens Healthineers' technological innovation to pioneer breakthroughs in healthcare for everyone, everywhere, sustainably, while advancing medical innovation and delivering excellence in patient care.
This press release and a press picture is available at:
https://www.siemens-healthineers.com/en-sg/press-room/press-releases-sg/shs-nuh-masld-research
The product/features mentioned in this press release is/are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details. The product and features mentioned in this press release are meant for healthcare professionals only.
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.
The National University Hospital (NUH) is Singapore's leading university hospital. While the hospital at Kent Ridge first received its patients on 24 June 1985, our legacy started from 1905, the date of the founding of what is today the NUS Yong Loo Lin School of Medicine. NUH is the principal teaching hospital of the medical school. Our unique identity as a university hospital is a key attraction for healthcare professionals who aspire to do more than practise tertiary medical care. We offer an environment where research and teaching are an integral part of medicine, and continue to shape medicine and transform care for the community we care for. We are an academic medical centre with over 1,200 beds, serving more than one million patients a year with over 50 medical, surgical and dental specialties. NUH is the only public and not-for-profit hospital in Singapore to provide trusted care for adults, women and children under one roof, including the only paediatric kidney and liver transplant programme in the country. The NUH is a key member of the National University Health System (NUHS), one of three public healthcare clusters in Singapore. For more information, visit www.nuh.com.sg
- Partnership will evaluate advanced ultrasound technologies to improve early detection and monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease
- Advancing ultrasound technologies that are safer, more accessible alternatives to invasive diagnostic procedures
- Research led by globally respected hepatologist Associate Professor Dan Yock Young
SINGAPORE, Oct. 8, 2025 /PRNewswire/ -- Siemens Healthineers and the National University Hospital (NUH) Singapore have announced a strategic research collaboration to advance diagnostic solutions for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects nearly 40% of adults in Singapore — a prevalence that is higher than the global average of 30.05%.
MASLD, formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), is now the most common cause of chronic liver disease worldwide. The elevated burden in Singapore reflects rising levels of obesity, sedentary lifestyles, and associated metabolic conditions – a serious trend that demands a more efficient, patient-friendly approach to liver care.
The research initiative will be led by Associate Professor Dan Yock Young, Senior Consultant, Division of Gastroenterology and Hepatology, Department of Medicine at NUH, and Associate Professor, Department of Medicine at the Yong Loo Lin School of Medicine, National University of Singapore. A globally respected hepatologist, his pioneering contributions to liver disease research have set international benchmarks. His leadership lends both clinical excellence and a global perspective to the project.
The collaborative study will evaluate Siemens Healthineers' cutting-edge ultrasound technologies: Ultrasound-Derived Fat Fraction (UDFF) and Auto Point Shear Wave Elastography (Auto pSWE). These tools enable physicians to non-invasively measure both liver fat and stiffness in a single, streamlined session, offering safer and more cost-effective alternatives to MRI scans and invasive biopsies. Early detection, more precise monitoring, and timely intervention could redefine the liver care pathway across the region.
"Together with NUH, led by Associate Professor Dan Yock Young, we will study how advanced ultrasound technologies can transform liver care by offering a cost-effective alternative to invasive biopsy or high-cost imaging," said Vy Tran, President Asia-Pacific Japan, Siemens Healthineers. "Our aim is to make ultrasound technologies accessible not only in tertiary hospitals but also at the polyclinic level. If we can embed these solutions into the liver care pathway, we can bring earlier detection, better monitoring and timely interventions to the people who need it. With this research collaboration, we hope to create new opportunities to scale the adoption of ultrasound technologies and improve clinical outcomes for liver patients across the Asia Pacific region."
"This collaboration represents an important step forward in addressing MASLD, which is fast emerging as a major health burden in Singapore," said Associate Professor Dan Yock Young. "At NUH, we combine deep clinical expertise in liver and metabolic health, backed by strong translational research. By working with partners such as Siemens Healthineers, we are well positioned to pioneer new approaches to detect, treat and prevent the disease, thereby helping more patients live healthier lives."
The initiative is part of the upcoming National University Centre for Digestive Health, set to open in January 2026, which aims to enhance patient access to cutting-edge diagnostic innovations.
"With nearly 40% of adults in Singapore affected, fatty liver disease is a silent epidemic we can no longer ignore. This collaboration reflects our shared responsibility to change that story. By bringing ultrasound innovation to the frontlines of care, we can empower physicians with better tools and offer patients not just accurate diagnostics, but hope for a healthier future," said Chaitanya Mehrotra, Head of Ultrasound, Asia Pacific, Siemens Healthineers.
This partnership leverages NUH's clinical expertise alongside Siemens Healthineers' technological innovation to pioneer breakthroughs in healthcare for everyone, everywhere, sustainably, while advancing medical innovation and delivering excellence in patient care.
This press release and a press picture is available at:
https://www.siemens-healthineers.com/en-sg/press-room/press-releases-sg/shs-nuh-masld-research
The product/features mentioned in this press release is/are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details. The product and features mentioned in this press release are meant for healthcare professionals only.
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2024, which ended on September 30, 2024, Siemens Healthineers had approximately 72,000 employees worldwide and generated revenue of around €22.4 billion. Further information is available at www.siemens-healthineers.com.
The National University Hospital (NUH) is Singapore's leading university hospital. While the hospital at Kent Ridge first received its patients on 24 June 1985, our legacy started from 1905, the date of the founding of what is today the NUS Yong Loo Lin School of Medicine. NUH is the principal teaching hospital of the medical school. Our unique identity as a university hospital is a key attraction for healthcare professionals who aspire to do more than practise tertiary medical care. We offer an environment where research and teaching are an integral part of medicine, and continue to shape medicine and transform care for the community we care for. We are an academic medical centre with over 1,200 beds, serving more than one million patients a year with over 50 medical, surgical and dental specialties. NUH is the only public and not-for-profit hospital in Singapore to provide trusted care for adults, women and children under one roof, including the only paediatric kidney and liver transplant programme in the country. The NUH is a key member of the National University Health System (NUHS), one of three public healthcare clusters in Singapore. For more information, visit www.nuh.com.sg
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Siemens Healthineers and National University Hospital Partner on Research to Advance Non-Invasive Liver Disease Diagnostics
SHENZHEN, China, Jan. 16, 2026 /PRNewswire/ -- RoboSense (02498 HKEX), a pioneering AI-driven robotics technology company, has been ranked No.1 in the 2025 3D LiDAR Sales Volume for Global Robotic Lawn Mowers by OFweek. Leveraging the generational-leading advantages of its digital LiDAR, such as the E1R, RoboSense has established deep partnerships with multiple global leading robotic lawn mower companies, including Mammotion and Segway Navimow. These collaborations have set a new benchmark for the next-generation boundary-free intelligent robotic lawn mowers driving industry development.
RoboSense's strong performance in the robotic lawn mower segment also drove record-breaking sales growth of its LiDAR products in the robotics sector in 2025, achieving an annual sales volume of 303,000 units—a year-on-year increase of 1141.8%. According to the Gaogong Industry Research Institute (GGII), "2025 Sales Volume Ranking of 3D LiDAR for Robotics in China," RoboSense ranked No.1 for LiDAR sales volume in the robotics sector, demonstrating leadership across both niche segments and the overall robotics market.
The robotic lawn mower segment was the fastest-growing robot category in 2025. According to IDC, in the first half of 2025 alone, global shipments of robotic lawn mowers reached 2.343 million units, representing a year-on-year increase of 327.2%. In this process, RoboSense's digital LiDAR, leveraging its self-developed SPAD-SoC and VCSEL digital chip architecture for high performance and reliability, has become a key driver in enabling perception upgrades and supporting market growth for robotic lawn mowers.
The E1R, the world's first fully solid-state digital LiDAR for robotics, features a 90° ultra-wide vertical FOV and 144 beams, allowing precise detection of small ground obstacles, terrain changes, and fence edges—facilitating accurate localization, mapping, and navigation for robotic lawn mowers. Its fully solid-state design ensures resilience to vibration, bumps, and shocks, improving operational stability on rough terrain by up to three times. Built to automotive-grade standards, the E1R has passed more than 60 reliability tests, including UV aging, salt spray, and electromagnetic compatibility, and can reliably operate in harsh conditions such as rain and dust. With an outdoor service life of up to 8 years, far exceeding industry standards, it serves as the optimal perception partner for all-weather, all-condition robotic lawn mower operation.
Leveraging its leading digital LiDAR products, RoboSense has become a core partner for multiple global leading robotic lawn mower companies. As the global market penetration of robotic lawn mowers continues to grow, the application of LiDAR is expected to enter a new phase of rapid expansion, with RoboSense poised to capitalize on its first-mover advantage and lead the way into the next era of strong growth.
Source:
OFWEEK, "2025 Global 3D LiDAR Sales Volume Ranking for Robotic Lawn Mowers"
Gaogong Industry Research Institute (GGII), "2025 Sales Volume Ranking of 3D LiDAR for Robotics in China"
About RoboSense
RoboSense (02498 HKEX), founded in 2014, is an AI-driven robotics technology company that supplies core components and solutions for the robotics market, committed to "Become the global leader in robotics technology platforms." Headquartered in Shenzhen, China, the company has offices in Shanghai, Suzhou, and Hong Kong; Stuttgart in Germany; Detroit and Silicon Valley in the United States.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
RoboSense Ranked No.1 in Global 3D LiDAR Sales Volume for Robotic Lawn Mowers
RoboSense Ranked No.1 in Global 3D LiDAR Sales Volume for Robotic Lawn Mowers
